Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had revenue of $13.68M in the quarter ending June 30, 2025, with 140.88% growth.

Revenue (ttm)

15.13M

Revenue Growth

-91.35%

P/S Ratio

1.78

Revenue / Employee

21.78K

Employees

272

Market Cap

10.52M

Revenue Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	-	-	-
Dec 31, 2024	-	-	-
Dec 31, 2023	60.28M	33.13M	122.05%
Dec 31, 2022	27.15M	21.00M	341.50%
Dec 31, 2021	6.15M	2.19M	55.36%
Dec 31, 2020	3.96M	2.84M	252.76%
Dec 31, 2019	1.12M	-58.38M	-98.11%
Dec 31, 2018	59.51M	21.67M	57.28%
Dec 31, 2017	37.83M	23.64M	166.47%
Dec 31, 2016	14.20M	5.22M	58.12%
Dec 31, 2015	8.98M	-892.00K	-9.04%
Jun 30, 2015	9.87M	9.05M	1,096.48%
Jun 30, 2014	825.00K	-	-
Jun 30, 2013	-	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Adaptimmune Therapeutics News

8 months ago - Adaptimmune Announces Changes to Board and Executive Leadership Team - Newsfile Corp
9 months ago - Adaptimmune Announces Delisting from Nasdaq - Newsfile Corp
1 year ago - Adaptimmune Reports Q2 Financial Results and Provides Business Update - Newsfile Corp
1 year ago - Adaptimmune Therapeutics Quarterly report: Q2 2025 - Filings
1 year ago - Adaptimmune Therapeutics Earnings release: Q2 2025 - Filings
1 year ago - Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds - Newsfile Corp
1 year ago - Adaptimmune Therapeutics Earnings Call Transcript: Q1 2025 - Transcripts
1 year ago - Adaptimmune Therapeutics Quarterly report: Q1 2025 - Filings

More News